Selectivity of pyripyropene derivatives in inhibition toward acyl-CoA:cholesterol acyltransferase 2 isozyme

Journal of Antibiotics

Volumn 61, Issue 8, 2008, Pages 503-508

  Ohshiro, Taichi ^a   Ohte, Satoshi ^a   Matsuda, Daisuke ^a   Ohtawa, Masaki ^a   Nagamitsu, Tohru ^a   Sunazuka, Toshiaki ^a   Harigaya, Yoshihiro ^a   Rudel, Lawrence L ^b   Omura, Satoshi ^a   Tomoda, Hiroshi ^a  

^a KITASATO UNIVERSITY   (Japan)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

ACAT isozyme; Acyl CoA:cholesterol acyltransferase (ACAT); Atherosclerosis; Semisynthetic pyripyropene derivative

Indexed keywords

ACYL COENZYME A CHOLESTEROL ACYLTRANSFERASE 1; ACYL COENZYME A CHOLESTEROL ACYLTRANSFERASE 2; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; ISOENZYME; N TERT BUTYL 1 METHYL 4,4 DIPHENYLBUTYLAMINE; PR 10; PR 109; PR 113; PR 118; PR 141; PR 146; PR 155; PR 156; PR 159; PR 163; PR 164; PR 165; PR 171; PR 218; PR 219; PR 220; PR 221; PR 222; PR 223; PR 25; PR 26; PR 31; PR 34; PR 45; PR 54; PR 55; PR 59; PR 60; PR 69; PR 70; PR 71; PR 72; PR 75; PR 86; PYRIPYROPENE A; PYRIPYROPENE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ARTICLE; DRUG SELECTIVITY; ENZYME INHIBITION; IC 50; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; CHO CELLS; CHOLESTEROL ESTERS; CRICETINAE; CRICETULUS; ENZYME INHIBITORS; INHIBITORY CONCENTRATION 50; ISOENZYMES; OLEIC ACID; PYRIDINES; RATS; SESQUITERPENES; STEROL O-ACYLTRANSFERASE; SUBSTRATE SPECIFICITY;

EID: 57849140891     PISSN: 00218820     EISSN: None     Source Type: Journal    
DOI: 10.1038/ja.2008.67     Document Type: Article

References (22)

1. Roth BD. ACAT inhibitors: Evolution from cholesterol-absorption inhibitors to antiatherosclerotic agents. Drug Disc Today 3: 19-25 (1998)
2. Kathawala, FG, Heider, JC. In Antilipidemic Drugs. (Ed. Witiak DT, Newman HAI, and Feller DR). Elsevier, New York, pp. 159-195 (1992)
3. Tardif JC, Gregoire J, L'Allier PL, Anderson TJ, Bertrand O, Reeves F, Title LM, Alfonso F, Schampaert E, Hassan A, McLain R, Pressler ML, Ibrahim R, Lesperance J, Blue J, Heinonen T, Rodes-Cabau J. Effects of the acyl coenzyme A: cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation 110: 3372-3377 (2004)
4. Nissen SE, Tuzcu EM, Brewer HB, Sipahi I, Nicholls SJ, Ganz P, Schoenhagen P, Waters DD, Pepine CJ, Crowe TD, Davidson MH, Deanfield JE, Winsniewski LM, Hanyok JJ, Kassalow LM. Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med 354: 1253-1263 (2006)
5. Tomoda H, Ōmura S. Potential therapeutics for obesity and atherosclerosis: inhibitors of neutral lipid metabolism from microorganisms. Pharmacol Ther 115: 375-389 (2007)
6. Ōmura S, Tomoda H, Kim YK, Nishida H. Pyripyropenes highly potent inhibitors of acyl-CoA:cholesterol acyltransferase produced by Aspergillus fumigatus. J Antibiot 46: 1168-1169 (1993)
7. Tomoda H, Kim YK, Nishida H, Masuma R, Ōmura S. Pyripyropenes, novel inhibitors of acyl-CoA:cholesterol acyltransferase produced by Aspergillus fumigatus. I. Production, isolation, and biological properties. J Antibiot 47: 148-153 (1994)
8. Kim YK, Tomoda H, Nishida H, Sunazuka T, Obata R, Ōmura S. Pyripyropenes, novel inhibitors of acyl-CoA:cholesterol acyltransferase produced by Aspergillus fumigatus. II. Structure elucidation of pyripyropenes A, B, C and D. J Antibiot 47: 154-162 (1994)
9. Obata R, Sunazuka T, Li Z, Tomoda H, Ōmura S. Structure-activity relationships of pyripyropenes, fungal acyl-CoA:cholesterol acyltransferase inhibitors. J Antibiot 48: 749-750 (1995)
10. Obata R, Sunazuka T, Tomoda H, Harigaya Y, Ōmura S. Chemical modification and structure-activity relationships of pyripyropenes; Potent, bioavailable inhibitor of acyl-CoA:cholesterol acyltransferase (ACAT). Bioog Med Chem Lett 5: 2683-2688 (1995)
11. Obata R, Sunazuka T, Li Z, Tian Z, Harigaya Y, Tabata N, Tomoda H, Ōmura S. Chemical modification and structure-activity relationships of pyripyropenes. 1. Modification at the four hydroxy groups. J Antibiot 49: 1133-1148 (1996)
12. Obata R, Sunazuka T, Kato Y, Tomoda H, Harigaya Y, Ōmura S. Chemical modification and structure-activity relationships of pyripyropenes. 2. 1,11-Cyclic analogs. J Antibiot 49: 1149-1156 (1996)
13. Obata R, Sunazuka T, Tian Z, Tomoda H, Harigaya Y, Ōmura S. Chemical modification and structure-activity relationships of pyripyropenes. 3. Synthetic conversion of pyridine-pyrone moiety. J Antibiot 50: 229-236 (1997)
14. Obata R, Sunazuka T, Tian Z, Tomoda H, Harigaya Y, Ōmura S, Smith III AB. New analogs of the pyripyropene family of ACAT inhibitors via α-pyrone fragmentation and d acylation/cyclization. Chem Lett 26: 935-936 (1997)
15. Chang CC, Huh HY, Cadigan KM, Chang TY. Molecular cloning and functional expression of human acyl-coenzyme A:cholesterol acyltransferase cDNA in mutant Chinese hamster ovary cells. J Biol Chem 268: 20747-20755 (1993)
16. Anderson RA, Joyce C, Davis M, Reagan JW, Clark M, Shelness GS, Rudel LL. Identification of a form of acyl-Co:cholesterol acyltransferase specific to liver and intestine in nonhuman primates. J Biol Chem 273: 26747-26754 (1998)
17. Cases S, Novak S, Zheng YW, Myers HM, Lear SR, Sande E, Welch CB, Lusis AJ, Spencer TA, Krause BR, Erickson SK, Farese RV Jr. ACAT-2, a second mammalian acyl-CoA:cholesterol acyltransferase. Its cloning, expression, and characterization. J Biol Chem 273: 26755-26764 (1998)
18. Oelkers P, Behari A, Cromley D, Billheimer JT, Sturley SL. Characterization of two human genes encoding acyl coenzyme A:cholesterol acyltransferase-related enzymes. J Biol Chem 273: 26765-26771 (1998)
19. Parini P, Davis M, Lada AT, Erickson SK, Wright TL, Gustafsson U, Sahlin S, Einarsson C, Eriksson M, Angelin B, Tomoda H, Ōmura S, Willingham MC, Rudel LL. ACAT2 is localized to hepatocytes and is the major cholesterol-esterifying enzyme in human liver. Circulation 110: 2017-2023 (2004)
20. Lada AT, Davis M, Kent C, Chapman J, Tomoda H, Ōmura S, Rudel LL. Identification of ACAT1- and ACAT2-specific inhibitors using a novel, cell-based fluorescence assay: individual ACAT uniqueness. J Lipid Res 45: 378-386 (2004)
21. Ohshiro T, Rudel LL, Ōmura S, Tomoda H. Selectivity of microbial acyl-CoA:cholesterol acyltransferase inhibitors toward isozymes. J Antibiot 60: 43-51 (2007)
22. Bligh EG, Dyer W. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37: 911-917 (1959)